glp-1 dental issues Ozempic Teeth: Protect Your Smile on WHO issues guidelines for GLP1
Description
As of 2026, Eli Lilly has progressed retatrutide into Phase 3 clinical trials, with data expected to inform regulatory submissions in the coming years [10]
Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al
Meier, J
Later in 2022, the FDA granted tirzepetide fast track designation for overweight and obesity in adults.6 To date, tirzepetide hasnt been FDA approved for weight loss (see table Current FDA-Approved Mono and Dual Agonists for details about weight management medications)
